MedDataX Logo

ADASUVE-Lorazepam Drug-Drug Interaction

NCT ID: NCT01877642

Last Updated: 2017-12-13

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will compare the safety and effects over time for giving both ADASUVE and lorazepam (intramuscular) compared to that of each agent given alone.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to compare the safety and pharmacodynamic profiles of concomitant administration of a single dose of ADASUVE and lorazepam (IM) compared to that of each agent administered alone. Respiratory pharmacodynamics will be monitored through recordings of respirations/minute and pulse oximetry. Other pharmacodynamic safety measures will include effects on blood pressure, heart rate, sedation and psychomotor measures of attention, information processing speed, reaction time, and coordination.

Initially, 4 subjects will receive lorazepam 1 mg IM + ADASUVE 10 mg open label to validate the dose regimen. After the safety data are reviewed and the dose regimen confirmed, 18 non-obese, healthy male or female volunteers between the ages of 18 and 50 will be enrolled in this double-blinded, double-dummy, randomized, 3-period cross-over drug interaction study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

ADASUVE inhaled loxapine drug drug interaction lorazepam acute treatment of agitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open Label (lorazepam 1 mg + Inhaled loxapine 10 mg)

Inhaled Staccato loxapine 10 mg + IM lorazepam 1 mg to confirm tolerability of combined treatment

Group Type OTHER

Lorazepam 1 mg IM

Intervention Type DRUG

Lorazepam 1 mg intramuscular

Inhaled loxapine 10 mg

Intervention Type DRUG

Inhaled Staccato loxapine 10 mg

Treatment Sequence ABC

Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg

Group Type OTHER

Lorazepam 1 mg IM

Intervention Type DRUG

Lorazepam 1 mg intramuscular

Inhaled loxapine 10 mg

Intervention Type DRUG

Inhaled Staccato loxapine 10 mg

Inhaled Placebo

Intervention Type DRUG

Inhaler with no drug in it to mimic the ADASUVE inhaler

Placebo IM

Intervention Type DRUG

intramuscular placebo to mimic lorazepam 1 mg IM

Treatment Sequence ACB

Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg

Group Type OTHER

Lorazepam 1 mg IM

Intervention Type DRUG

Lorazepam 1 mg intramuscular

Inhaled loxapine 10 mg

Intervention Type DRUG

Inhaled Staccato loxapine 10 mg

Inhaled Placebo

Intervention Type DRUG

Inhaler with no drug in it to mimic the ADASUVE inhaler

Placebo IM

Intervention Type DRUG

intramuscular placebo to mimic lorazepam 1 mg IM

Treatment Sequence BCA

Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg

Group Type OTHER

Lorazepam 1 mg IM

Intervention Type DRUG

Lorazepam 1 mg intramuscular

Inhaled loxapine 10 mg

Intervention Type DRUG

Inhaled Staccato loxapine 10 mg

Inhaled Placebo

Intervention Type DRUG

Inhaler with no drug in it to mimic the ADASUVE inhaler

Placebo IM

Intervention Type DRUG

intramuscular placebo to mimic lorazepam 1 mg IM

Treatment Sequence BAC

Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg

Group Type OTHER

Lorazepam 1 mg IM

Intervention Type DRUG

Lorazepam 1 mg intramuscular

Inhaled loxapine 10 mg

Intervention Type DRUG

Inhaled Staccato loxapine 10 mg

Inhaled Placebo

Intervention Type DRUG

Inhaler with no drug in it to mimic the ADASUVE inhaler

Placebo IM

Intervention Type DRUG

intramuscular placebo to mimic lorazepam 1 mg IM

Treatment Sequence CAB

Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg

Group Type OTHER

Lorazepam 1 mg IM

Intervention Type DRUG

Lorazepam 1 mg intramuscular

Inhaled loxapine 10 mg

Intervention Type DRUG

Inhaled Staccato loxapine 10 mg

Inhaled Placebo

Intervention Type DRUG

Inhaler with no drug in it to mimic the ADASUVE inhaler

Placebo IM

Intervention Type DRUG

intramuscular placebo to mimic lorazepam 1 mg IM

Treatment Sequence CBA

Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg

Group Type OTHER

Lorazepam 1 mg IM

Intervention Type DRUG

Lorazepam 1 mg intramuscular

Inhaled loxapine 10 mg

Intervention Type DRUG

Inhaled Staccato loxapine 10 mg

Inhaled Placebo

Intervention Type DRUG

Inhaler with no drug in it to mimic the ADASUVE inhaler

Placebo IM

Intervention Type DRUG

intramuscular placebo to mimic lorazepam 1 mg IM

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lorazepam 1 mg IM

Lorazepam 1 mg intramuscular

Intervention Type DRUG

Inhaled loxapine 10 mg

Inhaled Staccato loxapine 10 mg

Intervention Type DRUG

Inhaled Placebo

Inhaler with no drug in it to mimic the ADASUVE inhaler

Intervention Type DRUG

Placebo IM

intramuscular placebo to mimic lorazepam 1 mg IM

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ativan 1 mg IM ADASUVE 10 mg Staccato Placebo Saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female subjects between the ages of 18 to 50 years, inclusive.
* Body mass index (BMI) ≥18 and ≤32.
* Subjects who are willing and able to comply with the study schedule and requirements, and stay at the CRU for 9 days.
* Subjects who speak, read, and understand English and are willing and able to provide written informed consent on an IRB approved form prior to the initiation of any study procedures.
* Subjects who are in good general health prior to study participation as determined by a detailed medical history, physical examination, 12-lead ECG, blood chemistry profile, hematology, urinalysis, and in the opinion of the Principal Investigator.
* Female participants (if of child-bearing potential and sexually active) who agree to use a medically acceptable and effective birth control method throughout the study and for 30 days following the end of the study
* Male participants (if sexually active with a partner of child-bearing potential) who agree to use a medically acceptable and effective birth control method from the first dose and for 90 days following last dose of study drug. Male participants must refrain from donating sperm for the same period.

Exclusion Criteria

* Subject history, which includes: any cardiovascular disease or disorder; asthma, chronic obstructive lung disease, or any use of an inhaler prescribed for wheezing or bronchospasm must be excluded; sleep apnea; acute narrow-angle glaucoma; any neurological, gastrointestinal, hepatic, renal, hematologic, endocrine and/or metabolic disease or disorder; psychiatric illness or mental disorder except for short term situational anxiety or depression of \< 2 years duration; any substance abuse or addiction within the last 2 years; pregnancy within the past 6 months.
* Subjects who have taken prescription or nonprescription medication within 7 days of Visit 2.
* Subjects who have had an acute illness within the last 7 days of Visit 2.
* Subjects who have a history of HIV positivity.
* Subjects who test positive for alcohol or have a positive urine drug screen.
* Subjects who have a history of allergy or intolerance to loxapine or amoxapine.
* Subjects who have a history of allergy or intolerance to lorazepam or any other benzodiazepine.
* Subjects who have a history of allergy or intolerance to polyethylene glycol, propylene glycol, or benzyl alcohol
* Female subjects who have a positive pregnancy test at screening or at admission to Visit 2, or are breastfeeding.
* Subjects who have received an investigational drug within 30 days prior to the Screening Visit.
* Subjects who have any other disease(s), by history, physical examination, or laboratory abnormalities that, in the investigator's opinion, presents undue risk to the subject or may confound the interpretation of study results.
* Subjects who are considered by the investigator, for any reason, to be an unsuitable candidate for receiving lorazepam or ADASUVE.
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alexza Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Randall R Stoltz, MD

Role: PRINCIPAL_INVESTIGATOR

Medical Director, Covance-Evansville, Evansville, IN 47710

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Covance-Evansville

Evansville, Indiana, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Spyker DA, Cassella JV, Stoltz RR, Yeung PP. Inhaled loxapine and intramuscular lorazepam in healthy volunteers: a randomized placebo-controlled drug-drug interaction study. Pharmacol Res Perspect. 2015 Dec 17;3(6):e00194. doi: 10.1002/prp2.194. eCollection 2015 Dec.

Reference Type RESULT
PMID: 27022468 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AMDC-204-402

Identifier Type: -

Identifier Source: org_study_id